2-(4-Bromo-phenylamino)-1-p-tolyl-ethanone | 146537-27-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(4-Bromo-phenylamino)-1-p-tolyl-ethanone
• 英文别名: 2-(4-bromoanilino)-1-(4-methylphenyl)ethanone
• CAS: 146537-27-1
• 化学式: C₁₅H₁₄BrNO
• 分子量: 304.186
• InChiKey: WTTXLGNHKBNWNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-Bromo-phenylamino)-1-p-tolyl-ethanone 在 sodium hydroxide 、 4-溴苯铵溴化物 、 zinc(II) chloride 作用下， 以 乙醇 、 苯 为溶剂， 反应 30.0h， 生成 1-(4-Bromo-phenyl)-2-methyl-4-p-tolyl-1H-pyrrole-3-carboxylic acid
  参考文献：
  名称：

  Research on antibacterial and antifungal agents. VIII. synthesis and antimicrobial activity of 1,4-diarylpyrroles

  摘要：

  The synthesis and the antimicrobial activity of 1,4-diarylpyrroles are reported. The obtained data in comparison with pyrrolnitrin show that many acid derivatives 4 exhibit a selective activity against some strains of Candida spp and poor activity against strains of Candida albicans. All ester derivatives 3 are inactive. The results obtained are discussed on the basis of structure-activity relationships.

  DOI：

  10.1016/0223-5234(92)90092-f
• 作为产物：
  描述：

  2-溴-4'-甲基苯乙酮 、 4-溴苯胺 以 乙醇 为溶剂， 反应 4.0h， 以70%的产率得到2-(4-Bromo-phenylamino)-1-p-tolyl-ethanone
  参考文献：
  名称：

  Research on antibacterial and antifungal agents. VIII. synthesis and antimicrobial activity of 1,4-diarylpyrroles

  摘要：

  The synthesis and the antimicrobial activity of 1,4-diarylpyrroles are reported. The obtained data in comparison with pyrrolnitrin show that many acid derivatives 4 exhibit a selective activity against some strains of Candida spp and poor activity against strains of Candida albicans. All ester derivatives 3 are inactive. The results obtained are discussed on the basis of structure-activity relationships.

  DOI：

  10.1016/0223-5234(92)90092-f

文献信息

• [EN] CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE LA CÉRAMIDE GALACTOSYLTRANSFÉRASE POUR LE TRAITEMENT DE MALADIES
  申请人：BIOMARIN PHARM INC

  公开号：WO2017214505A1

  公开（公告）日：2017-12-14

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物、以及使用这种化合物治疗或预防与酶神经鞘糖脂转移酶（CGT）相关的疾病或紊乱的方法，例如溶酶体贮积症。溶酶体贮积症的例子包括 Krabbe 病和白质变性白血病。